ICO Therapeutics Inc.
ICO Therapeutics Inc. is listed today as Satellos Bioscience Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2024 | $25 M | No. 4 | $10 to $50 million | equity, options | SEC | |
| May 2023 | $33 M | No. 3 | $10 to $50 million | equity, options | SEC | |
| Jan 2014 | $2 M | No. 2 | $2 to $10 million | equity, options | SEC | |
| Oct 2009 | $3 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
ICO Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).
SEC Form D · Jan 2025
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jan 2025
That is all the official record says: ICO Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of ICO Therapeutics Inc. are on record.
Investors#
No investor of ICO Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 16 investors.
Largest shareholders today
Institutions holding Satellos Bioscience Inc. shares, as of Sep 30, 2026.
- Franklin Templeton Inc$8 M4.41%
- Siren, L.L.C.$8 M4.19%
- Vivo Capital, LLC$7 M3.82%
- Point72 Asset Management, L.P.$6 M3.20%
- Sphera Funds Management LTD.$5 M3.00%
- Saturn V Capital Management LP$4 M2.43%
- Woodline Partners LP$4 M2.35%
- Montanova Capital, LLC$4 M2.23%
- Stonepine Capital Management, LLC$4 M2.14%
- 683 Capital Management, LLC$3 M1.67%
- Soleus Capital Management, L.P.$3 M1.55%
- ADAR1 Capital Management, LLC$2 M1.21%
- Millennium Management LLC$2 M1.19%
- AWM Investment Company, Inc.$2 M0.85%
- Avidity Partners Management LP$1 M0.77%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Courtney D. Wells | Executive officer | Jan 2025 |
| Elizabeth Williams | Executive officer | Jan 2025 |
| Frank Gleeson | Executive officer | Jan 2025 |
| Michael Robert Cross | Executive officer | Jan 2025 |
| Michael Rudnicki | Executive officer | Jan 2025 |
| Philip D. Lambert | Executive officer | Jan 2025 |
| J. Robert Hall | Executive officer | May 2023 |
| Warren Whitehead | Executive officer | May 2023 |
| Andrew J. Rae | Executive officer | Feb 2014 |
| Peter G. Hnik | Executive officer | Feb 2014 |
| W. John Meekison | Executive officer | Feb 2014 |
| Andrew John Rae | Executive officer | Dec 2009 |
| John John Clement | Executive officer | Dec 2009 |
| Peter John Hnik | Executive officer | Dec 2009 |
| Santa Jeremy John Ono | Executive officer | Dec 2009 |
| Adam Mostafa | Director | Jan 2025 |
| Bill Jarosz | Director | Jan 2025 |
| Brian Bloom | Director | Jan 2025 |
| Frank Gleeson | Director | Jan 2025 |
| Franklin D. Berger | Director | Jan 2025 |
| Geoff MacKay | Director | Jan 2025 |
| Rima Al-awar | Director | Jan 2025 |
| Stephanie D. Brown | Director | Jan 2025 |
| William McVicar | Director | Jan 2025 |
| Andrew J. Rae | Director | Feb 2014 |
| Douglas G. Janzen | Director | Feb 2014 |
| Noel J. Hall | Director | Feb 2014 |
| Richard J. Barker | Director | Feb 2014 |
| William J. Jarosz | Director | Feb 2014 |
| Andrew John Rae | Director | Dec 2009 |
| John John Clement | Director | Dec 2009 |
| Noel John Hall | Director | Dec 2009 |
| Richard John Barker | Director | Dec 2009 |
| William John Jarosz | Director | Dec 2009 |
| Frank Gleeson | Promoter | Jan 2025 |
Went public since 2026. Its SEC number is that of a company listed on a stock exchange.